Biological Effects and Use of PrPSc- and PrP-Specific Antibodies Generated by Immunization with Purified Full-Length Native Mouse Prions

Benjamin Petsch,1†* Andreas Müller-Schiffmann,2† Anna Lehle,1 Elizabeta Zirdum,1 Ingrid Prikulis,2 Franziska Kuhn,3 Alex J. Raeber,3 James W. Ironside,4 Carsten Korth,2 and Lothar Stitz1

Friedrich-Loeffler-Institut, Institute of Immunology, Tuebingen,1 and Department of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf,2 Germany; Prionics AG, Schlieren, Switzerland3; and National Creutzfeldt-Jakob Disease Surveillance Unit, University of Edinburgh, Edinburgh, United Kingdom4

Received 24 November 2010/Accepted 15 February 2011

The prion agent is the infectious particle causing spongiform encephalopathies in animals and humans and is thought to consist of an altered conformation (PrPSc) of the normal and ubiquitous prion protein PrPC. The interation of the prion agent with the immune system, particularly the humoral immune response, has remained unresolved. Here we investigated the immunogenicity of full-length native and infectious prions, as well as the specific biological effects of the resulting monoclonal antibodies (MAbs) on the binding and clearance of prions in cell culture and in vivo. Immunization of prion knockout (Prnp0/0) mice with phosphotungstic acid-purified mouse prions resulted in PrP-specific monoclonal antibodies with binding specificities selective for PrPSc or for both PrPC and PrPSc. PrPSc-specific MAb W261, of the IgG1 isotype, reacted with prions from mice, sheep with scrapie, deer with chronic wasting disease (CWD), and humans with sporadic and variant Creutzfeldt-Jakob disease (CJD) in assays including a capture enzyme-linked immunosorbent assay (ELISA) system. This PrPSc-specific antibody was unable to clear prions from mouse neuroblastosoma cells (ScN2a) permanently infected with scrapie, whereas the high-affinity MAb W226, recognizing both isoforms, PrPSc and PrPC, did clear prions from ScN2a cells, as determined by a bioassay. However, an attempt to treat intraperitoneally infected mice with full-length W226 or with a recombinant variable-chain fragment (scFv) from W226 could only slightly delay the incubation time. We conclude that (i) native, full-length PrPSc elicits a prion-specific antibody response in PrP knockout mice, (ii) a PrPSc-specific antibody had no prion-clearing effect, and (iii) even a high-affinity MAb that clears prions in vitro (W226) may not necessarily protect against prion infection, contrary to previous reports using different antibodies.

Prions (PrPSc), the abnormal conformational isoforms of the cellular prion protein (PrPC), are responsible for invariably fatal neurodegenerative diseases of humans and animals (1, 35). Because they are transmissible and thereby induce characteristic morphological changes in the brains of affected individuals, these diseases have been termed transmissible spongiform encephalopathies (TSE). The current “protein-only” hypothesis postulates conformational changes of PrPC resulting in the infectious, abnormal, β-sheet-rich, insoluble, multimeric pathological isoform PrPSc in the absence of a specific nucleic acid or any other known infectious particle (39). Recent experiments with recombinant prion protein biochemically manipulated to result in the formation of infectious PrPSc strongly support the “protein-only” hypothesis (10, 22, 23).

Even though the primary amino acid sequence is the same for both the cellular and pathogenic PrP isoforms (5, 29), the two isoforms of PrP show considerable differences in their folding (31), leading to different biochemical properties that can be used to distinguish PrPC from PrPSc (7, 24). In particular, the partial resistance of PrPSc to treatment with protease K (PK), which contrasts with the sensitivity of the cellular form PrPC to this enzyme, has been used in the past to distinguish between these two isoforms (24). However, this indirect detection method for PrPSc has many disadvantages, because, for example, PK digestion of PK-sensitive prions may lead to false-negative results (38).

The generation of antibodies specific for the pathological isoform PrPSc was greatly accelerated by the availability of prion protein knockout (Prnp0/0) mice (9, 36). So far, various antigens had been used to generate monoclonal antibodies (MAbs), including PrP-encoding DNA and RNA (20, 21), recombinant PrP (19, 34, 42), synthetic peptides (2, 15, 30, 45), and scrapie-infected tissue culture cells (28). The first monoclonal antibody showing specificity for PrPSc, 15B3, had been obtained after immunization of Prnp0/0 mice with recombinant bovine PrP (19). Immunization of mice with a sequence comprising repetitions of the short peptide motif YYR yielded MAbs exclusively precipitating PrPSc from sheep with scrapie and from Creutzfeldt-Jakob disease (CJD) patients (32). Finally, Moroncini and coworkers cloned recombinant antibodies with specificity for PrPSc by grafting a prion protein peptide into an IgG antibody against HIV-1 Env (25, 26, 40).

In spite of the publication of several PrPSc-specific monoclonal antibodies in recent years (19, 25, 26, 32, 40), the therapeutic potential of such antibodies has not yet been reported. Here we investigated the antibody immune response to so-
dium phosphotungstic acid (NaPTA)-precipitated full-length infectious PrPSc and evaluated the resulting antibodies by conformation specificity and their ability to cure prion infections \textit{in vitro} and \textit{in vivo}.

**MATERIALS AND METHODS**

**Mice.** C57BL/10, NPr/Pr (9), Tg33 (37), and BALB/c mice were bred at the Friedrich-Loeber-Institut (FLI), Tübingen, Germany. Transgenic mice were a kind gift from C. Weissmann and A. Aguzzi. Infected mice were monitored twice a week initially and then daily after the development of clinical symptoms. Mice were terminated in the end stage of disease. The number of mice and the experimental design had been approved by local authorities (Regional Board; permission numbers FLI 204/02 and FLI 216/04). All experiments were conducted in compliance with German and European laws and guidelines for animal protection.

**TSE strains.** An RML strain seed of the scrapie scrapie agent was kindly provided by U. Agrimi and F. Scholl, Italy. Samples from mock-infected white-tailed deer (infected with a control brain homogenate) (samples 103 and 123) and samples from white-tailed deer with chronic wasting disease (CWD) (samples 106, 112, and 121) were a kind gift from E. Hoover, Colorado State University. Variant CJD (vCJD) samples for the capture enzyme-linked immunosorbent assay (ELISA) consisted of two reference probes from the WHO (NHBB00003 and NHBB00014). Samples from cases of sporadic CJD and genetic CJD were obtained from the German TSE Forum. Experiments with scrapie strains and CWD strains were performed at the biosafety level 2 laboratories of the FLI. Experiments using various CJD strains were conducted at the Institute of Neuropathology of the University of Duesseldorf or at Prionics AG, Schlieren, Switzerland, in authorized laboratories.

**Cell lines.** Bos2 cells (8) were a kind gift from A. Aguzzi, and ScN2a cells were obtained from S. Prusiner, San Francisco, CA.

**Immunization with native NaPTA-precipitated RML.** For immunization, 250 μl of a 10% brain homogenate of terminally scrapie infected CD1 mice, infected with the RML strain, was precipitated with NaPTA as described previously (43). The resulting pellet was dissolved in phosphate-buffered saline (PBS) and was mixed with an adjuvant. The first and second immunizations were performed intraperitoneally (i.p.) using the ABM-ZK adjuvant (Linaris, Germany), whereas for booster immunizations, the ABN adjuvant (Linaris, Germany) was used. Mice were immunized four times with NaPTA precipitates equivalent to 250 μl of 10% brain homogenate of terminally scrapie infected CD1 mice. The last booster injection was performed intravenously (i.v.) without adjuvant 4 days prior to fusion. Mouse sera were monitored for PrP immunoreactivity by Western blotting. Spleen cells were fused to P3X63Ag8×653 cells by using a modified protocol of Köhler and Münstermann (17).

**Cultivation of hybridomas.** Hybridomas were grown in 96-well plates using minimal essential medium (MEM) with nonessential amino acids (NEAA) ( Gibco, Invitrogen, Karlsruhe, Germany) and 10% fetal calf serum (FCS), and antibody production was monitored by use of an immunoglobulin-detecting ELISA.

**Screening for PrP-specific antibodies.** First, an ELISA using recombinant mouse prion protein determined antibody specificity for PrP. All reacting hybridoma supernatants were then verified by Western blotting on RML-infected mouse prion protein determined antibody specificity for PrP. All reacting hybridoma supernatants were added for 1 h at RT. The ELISA was developed using horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Dianova, Hamburg, Germany) in combination with 2.2'-azino bis(3-ethylbenzthiazolinesulfonic acid) (ABTS; Roche, Mannheim, Germany), and absorbance was measured in a Sunrise ELISA reader (Tecan, Crailsheim, Germany). Hybridoma supernatants showing a stronger reaction with the scrapie brain homogenate than with the control brain homogenate were further tested by immunoprecipitation.

**Immunoprecipitation of prion protein.** For immunoprecipitation, 1% brain homogenate in Tris-buffered saline (TBS) with 0.3% sarcosyl was incubated with a MAb overnight at 4°C. Precipitation was performed using formalin-fixed Staphylococcus aureus for IgM or Pansorbin cells for IgG isotypes (Calbiochem, Merck, Darmstadt, Germany). After washes, precipitates were boiled and then centrifuged for 1 min at 13,000 rpm, and the complete supernatant was used for Western blotting.

**SPR analysis.** Binding kinetics was determined on a Biacore 1000 instrument (Biacore AB, Uppsala, Sweden). Recombinant mouse PrP (1 μM) was diluted in 0.3 M sodium acetate (pH 4.5) and was immobilized on a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)–N-hydroxysuccinimide (NHS)-activated CMS chip (Biacore) at 5 μl/min. After immobilization and blocking with ethanolamine, the chip was washed with 50 mM NaOH until a steady signal was obtained. The final surface density was about 3,500 response units (RU). All kinetic surface plasmon resonance (SPR) analyses were run at a 5-μl/min PBS flow, and the antibody was injected at different concentrations ranging from 10 to 200 nM. Association and dissociation were each recorded for 180 s. After each cycle, the system was regenerated with 50 mM NaOH. Kinetic data were calculated using BIAevaluation, version 4.1, software according to the bivalent analyte model.

**Immunohistological staining of PrP.** Brains of infected and control mice were fixed in 4% formalin and subsequently were treated with concentrated formic acid for 1 h. After a wash with PBS, the brains were postfixed again using 4% formalin. Sections (thickness, 4 μm) were autoclaved in citrate buffer and were treated with proteinase K for 5 min at 37°C using a Digest-All kit (Zymed). Slices were stained using an HRP-conjugated secondary antibody (SuperPicture-HP Polymer Conjugate kit; Zymed, Invitrogen, Karlsruhe, Germany) for 10 min. Signal amplification was performed using the Tyramide Signal Amplification (TSA) kit (Perkin-Elmer, Rodgau, Germany), and the signal was developed using diaminobenzidine (DAB substrate kit for peroxidase; Vector Laboratories, Peterborough, United Kingdom). Brain slices were counterstained using hematoxylin.

**Treatment of ScN2a cells.** ScN2a cells were cultured in the presence of a monoclonal antibody at various concentrations. At the indicated time points (see Fig. 5), cells were again subcultured in the presence or absence of the antibody. One subculture was treated with monoclonal antibody W226 for 21 days, and then all cultures were continued in the absence of the antibody. For bioassays, mice were injected intracerebrally (i.c.) with 2 × 10⁵ cells per mouse. The infectious titer of inoculated cells was calculated according to reference 16. Cultures of ScN2a cells were treated in the presence of antibody W261 for as long as 104 days. For cell blot analysis, all cells were seeded in parallel and grown to confluence. Coverslips in 24-well plates were cultured and were further subcultured for 2 further days. Cell blot analysis for the detection of scrapie prion protein was performed as described elsewhere (8).

**ELISA with Mab W261 and 6H4-HRP.** A 25-μg/ml portion of Mab W261 was diluted into PBS and applied to 96-well Nunc MaxiSorp plates for 2 h at room temperature. After three washes with PBS-Tween (PBST), wells were blocked with 0.1% BSA in PBS for 1 h. Ten percent brain homogenates in homogenization buffer (Prionics AG) were diluted 1:100, 1:500, and 1:1,000 in immuno-precipitation buffer (Prionics AG) and were incubated for 2 h at room temperature. After three washes with PBST, bound PrP was denatured for 15 min at 95°C using an HRP-conjugated secondary antibody (Prionics AG). Prion protein was detected using 10 ng/ml Mab 6H4 conjugated to HRP (Prionics AG) diluted in PBS containing 0.05% Tween 20 and 0.1% BSA. Unbound detection antibody was washed away with PBST, and a luminescence signal was generated using the SuperSignal ELISA Femto maximum-sensitivity substrate (Pierce). The readout was performed using the MPL2 microplate luminometer (Berthold).

**Production of antibody W226 and scFv W226 for therapy.** Large amounts of Mab W226 were generated by culture of hybridoma cells in cell spin bottles using MEM-NEAA (Gibco, Invitrogen, Karlsruhe, Germany) with 10% ultralow IgG FCS (PAN Biotech, Aidenbach, Germany) to prevent contamination with bovine IgG molecules. Cultures were grown at 37°C under 5% CO₂, until the amount of hybridoma cells started to decrease. The culture medium was harvested, and cells and cell debris were separated from the antibody-containing medium by centrifugation at 1,200 rpm in a Beckman J-6 centrifuge. Supernat-

Vol. 85, 2011 EFFECTS AND USE OF PrPSc- AND PrP-SPECIFIC ANTIBODIES 4539
TABLE 1. Binding of monoclonal antibodies generated in this study to PrP of different species

<table>
<thead>
<tr>
<th>Species</th>
<th>Binding of:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>W123</td>
</tr>
<tr>
<td>Cats</td>
<td>–</td>
</tr>
<tr>
<td>Cattle</td>
<td>–</td>
</tr>
<tr>
<td>Deer</td>
<td>+</td>
</tr>
<tr>
<td>Dogs</td>
<td>–</td>
</tr>
<tr>
<td>Hamsters</td>
<td>+</td>
</tr>
<tr>
<td>Llamas</td>
<td>–</td>
</tr>
<tr>
<td>Humans</td>
<td>–</td>
</tr>
<tr>
<td>Mice</td>
<td>+</td>
</tr>
<tr>
<td>Moufflons</td>
<td>–</td>
</tr>
<tr>
<td>Pigs</td>
<td>–</td>
</tr>
<tr>
<td>Sheep</td>
<td>–</td>
</tr>
</tbody>
</table>

The specificity of the antibodies was determined using Western blotting.

b –, no binding; +/+, background binding; +/+, weak binding; +, strong binding.

RESULTS

Antigen preparation and screening of monoclonal antibodies. As an immunogen, an enriched and highly purified preparation of PrPSc obtained by NaPTA precipitation of mouse scrapie strain RML (RML6) was obtained by a method described by others (43). Since, to our knowledge, the infectivity of NaPTA-precipitated pathological prion protein for mice had not been reported previously, we first analyzed this biological property of the purified antigen by inoculating the pre-}

ants were stored at −20°C until the antibody was purified by affinity chromatography using protein A Sepharose (Amersham, Freiburg, Germany). scFv W226 was expressed as described previously (27).

Statistical analysis. Survival times for different groups of mice in treatment experiments were compared using GraphPad Prism, version 5, software. Groups were compared by using the Mann-Whitney two-tailed t test.

FIG. 1. Reaction patterns of PrPSc-specific MAbs in immunoprecipitation (IP). (A) MAbs W68 and W261 react exclusively with the PrPSc isoform. (B and C) Treatment of precipitates with PK reveals the presence of PK-resistant PrPSc in MAb-precipitated material for W261 (B) and W68 (C). (D) Treatment of samples with PK prior to immunoprecipitation with MAB W261 reveals the interaction of W261 with the PK-resistant core of PrPSc. (E) (Right) Specific immunoprecipitation from brain samples of deer with CWD. The presence of PrP is demonstrated by the presence of PK-resistant PrPSc in MAb-precipitated material for W261 (lower left). W261 reacts with CWD-affected brain samples but not with control brain samples, kindly provided by E. Hoover. Immunoprecipitations were performed using 200 µl of 1% brain homogenate. For input material, 30 µl of 1% brain homogenate was loaded per lane. Western blots using mouse tissue homogenates and complete supernatants of boiled precipitates were analyzed by Western blotting. For input material, 30 µl of 1% brain homogenate was loaded per lane. Western blots using mouse tissue were developed using antibody W226. Prion proteins on immune blots with human tissue were detected using MAb 6H4 (19). For the detection of prion proteins of animal species other than mouse, antibody POM-1 was used (34). The signal at 50 kDa corresponds to the heavy chain of mouse immunoglobulin.
tein (Fig. 1B and C). Furthermore, when PK-digested prion-infected mouse brain was used for immune precipitation, MAb W261 also proved specific for PrPSc, and its conformational epitope was then inferred to be within the PK-resistant core (Fig. 1D).

**Biochemical characteristics and detection abilities of PrPSc-specific MAb s.** Since W68 and W261 essentially yielded the same results, W261 was chosen for all further experiments because of its preferable IgG isotype. MAb W261 was then used for detecting reactivities against PrPSc, and its conformational epitope was then inferred to be within the PK-resistant core (Fig. 1D).

**Additional experiments examined the specificity of MAb W261 for CWD of white-tailed deer.** As shown in Fig. 1F, MAb W261 specifically precipitated PrPSc from the brains of three CWD-diseased white-tailed deer, but not from mock-infected controls. In contrast, MAb W226, used as a control, was able to detect both isoforms of the deer prion protein in uninfected and infected brain samples.

For human prion diseases, MAb W261 specifically recognized all pathological isoforms of CJD strains but did not react with human control brains (Fig. 2A and B). The amount of immunoprecipitated material from brain homogenates with different CJD strains was variable but, with the exception of genetic CJD, consistent with the different amounts of PrPSc present in the homogenates used for immunoprecipitation, as verified by proteinase K digestion and detection by antibody 6H4 (Fig. 2C).

FIG. 2. Immunoprecipitation of PrPSc from CJD samples with MAb W261. (A) Detection of PrPSc in various sporadic (s) cases and one genetic (g) case of CJD. (B) Detection of PrPSc in various CJD cases, including vCJD. (C) Demonstration of various amounts of PrPSc in spontaneous, genetic, and variant CJD cases tested in panels A and B by Western blotting. Immunoprecipitations were performed using 1 ml of 1% brain homogenate, and complete supernatants of boiled precipitates were analyzed by Western blotting. For input material, 30 μl of 1% brain homogenate was loaded per lane. The signal at 50 kDa corresponds to the heavy chain of mouse immunoglobulin.

FIG. 3. ELISA with MAb W261 as the capture antibody for the detection of PrPSc. (A) Detection of sheep PrPSc; (B) detection of vCJD PrPSc. The specificity of this capture ELISA is demonstrated for sheep scrapie (A) and for vCJD (B). For each species, a control homogenate from normal brains was only weakly recognized, whereas the homogenate from scrapie- or vCJD-affected brains was clearly detected in a dose-dependent manner. In conclusion, this sandwich ELISA using MAb W261 is able to distinguish between TSE-infected and uninfected tissue homogenates of sheep or humans without the need for proteinase K digestion, demonstrating its usefulness for diagnostic assays. Negative controls (neg) are uninfected sheep or human brain homogenates. One microliter of 10% or further diluted brain homogenate was used per sample in a volume of 200 μl. The results are given as relative light units (RLU). The proportions above the graphs represent the values obtained divided by the value for the negative control.

Conformation-insensitive specificity of MAb W226. Within the same fusion, PrPSc-specific antibodies W68 and W261 were identified, along with antibodies recognizing PrPC and PrPSc equally well (W123, W187, W226, W756, and W827). For one of the latter (W226), Biacore analysis demonstrated an exceptionally strong dissociation constant for recombinant mouse...
prion protein, $523 \times 10^{-12}$ M (Fig. 4A). Relative conformation insensitivity was determined by immunoprecipitation (data not shown), immunohistochemistry under denaturing conditions (Fig. 4B), and comparable detection of surface and intracellular PrP on both infected and uninfected mouse neuroblastoma cells (Fig. 4C and D), showing that this antibody detected PrP by all assays used, including denatured Western blotting, independent of the PrP conformation.

**Differential biological activity of PrPSc-specific and universal PrP antibodies in permanently scrapie infected cell lines.**
The capacities of the MAbs resulting from immunizations with purified infectious prions for shielding prions during cellular replication were assessed in cell models of prion infection. We tested whether the PrPSc-specific MAb W261 was also able to reduce PrPSc levels in ScN2a cells. ScN2a cells were cultivated in the presence of MAb W261 for more than 100 days and were regularly tested for the presence of PrPSc by cell blot assays (Fig. 5C). Culture of ScN2a cells in the presence of even large amounts of MAb W261 (50 µg/ml) did not reduce PrPSc contents in these cells at any time point analyzed, demonstrating the absence of therapeutic potential of the PrPSc-specific MAb W261.

In contrast, as demonstrated by cell blot analysis, culture of cells for 9 days or more in the presence of 10 µg/ml MAb W226 resulted in a significant reduction in the level of PrPSc after proteinase K treatment (Fig. 5A). In an experiment where antibody treatment was discontinued after 31 days and cells were passaged for 42 to 88 days, no PrPSc reappeared, proving complete clearance of prions (Fig. 5B).

To confirm the efficiency of MAb W226 in curing cells from PrPSc, antibody-treated cells were tested in bioassays by i.c. inoculation into tga20 mice. Whereas mice inoculated with untreated ScN2a control cells succumbed to scrapie after 84 ± 5 days, corresponding to 2.56 log LD50 (50% lethal dose), those mice injected with cells treated for 12 days with MAb W226 had to be sacrificed after 102 ± 8 days, corresponding to 0.94 log LD50, and treatment for 31 days did not result in disease and death, even after an observation period of >500 days (Fig. 5D). From these experiments we concluded that MAb W226 is capable of curing scrapie-infected cells and therefore might be a potential therapeutic antibody for curing prion infection *in vivo*.

**Treatment of scrapie-infected mice with monoclonal antibody W226 and scFvW226.** In their landmark paper, White et al. (44) demonstrated that an exogenously administered antibody was able to prevent an intraperitoneal prion infection, suggesting that postexposure treatment of prion infection was possible. We therefore tested the high-affinity MAb W226, which binds to the same epitope as a MAb active against prions from the study by White et al., in exactly the same experimen-
tal setup. In addition, we cloned a recombinant variable-chain fragment (scFv) from W226 into Escherichia coli and demonstrated its in vitro antiprion activity by a bioassay (27).

C57BL/6 mice were infected intracerebrally and intraperitoneally with a 10^10 or 10^7 dilution of a 20% brain homogenate of the RML strain of the mouse-adapted scrapie agent. The infectious titer of RML had been determined to be high enough to lead to prion disease for all mice inoculated. Twenty-eight days after infection, treatment of infected mice with a monoclonal antibody or single-chain antibody fragment was started, using 2 mg/mouse/day (W226) or 1 mg/mouse/day (scW226) twice a week by intraperitoneal injection. Treatment of mice infected via the i.c. route did not exhibit any prolongation in the incubation period at all (data not shown), consistent with previous data (44). Mice infected i.p. demonstrated minimal prolongation of the incubation period when treated for 10 weeks (Fig. 6A). Most of the mice treated for a much longer period also exhibited minimal prolongation of the incubation time, but one mouse in each group did not develop symptoms of scrapie for 677 (scW226) or 694 (W226) days postinfection (dpi), even when treatment was terminated at 320 dpi. Differences in mean incubation time between all treated groups and the untreated group were statistically significant (Fig. 6A) but did not result in the highly efficient therapeutic impact, securing the survival of all peripherally infected mice, that was described previously (44).

Differences between mice treated for 70 or 320 days were not significant (P, 0.8413 for W226 and 1 for scW226), and since there was no statistically significant difference between groups treated with scW226 or W226 (P, 1 for 70 days and 0.8413 for 320 days of treatment), we conducted a second treatment experiment using scW226 with a reduced incubation time. In the second experiment, the impact of starting antibody treatment of mice at 2 dpi was studied, and mice were treated with 2 mg/mouse (W226) or 1 mg/mouse (scW226) twice a week. Symbols represent individual mice, and horizontal lines indicate the median incubation times. C57BL/6 mice were inoculated using dilutions of a 20% homogenate: 10^10 dilution for i.c. inoculation and 100 dilution for i.p. inoculation. The endpoint titer of the scrapie pool used for the inoculation of mice was determined by i.c. inoculation of tga20 mice and was calculated to be 10.6 log LD50 per g of brain according to the method of Reed and Muench (37a).
scW226 for 66 days. This treatment also resulted only in a minimal, though highly significant \((P, 0.0035)\), increase in the incubation time and therefore confirmed the results of the earlier trial (Fig. 6B).

The limited impact of treatment with MAb W226 or scW226 on the development of disease by peripherally infected mice, in view of the strong effect in clearing prions from ScN2a cells (Fig. 5), contrasts sharply with the great therapeutic benefit of antibody therapy reported previously (44).

**DISCUSSION**

Our findings can be summarized in three major points, as follows. (i) Full-length infectious prions are immunogenic in PrP knockout mice and lead to an antibody response that includes the generation of PrPSc-specific antibodies, as well as universal PrP-recognizing antibodies. (ii) A highly PrPSc specific IgG1 subtype MAb, W261, was unable to cure ScN2a cells. (iii) A high-affinity anti-PrP antibody, W226, or its recombinant scFv was able to cure ScN2a cells but unable to protect from an intraperitoneal prion infection when administered in vivo.

The availability of PrPSc-specific antibodies for diagnostic and therapeutic purposes has been a long-sought goal. Here we could show that PrPSc conformation specificity is part of an immune response elicited in prion-immunized mice, although in this study, PrP knockout mice with an enlarged epitope space for PrP were used. NaPTA-precipitated pathological prion protein is highly polymeric, as demonstrated by electron microscopy (38). It is therefore reasonable to argue that the polymeric nature of the NaPTA-precipitated antigen is responsible for the induction of a strong antibody response, as has been exemplified by the work of Bachmann et al. with polymers of the viral glycoprotein (GP) of vesicular stomatitis virus (VSV), showing stronger B-cell responses to polymers than to monomers of the GP (3). This stronger stimulation of the immune response is thought to be induced by B-cell receptor cross-linking through the highly ordered GP that is found on the viral surface of VSV (4). Therefore, we assume that the polymeric nature of the NaPTA-precipitated PrPSc is also able to induce a strong B-cell response against PrPSc.

The potential usefulness of W261 for diagnostic purposes was demonstrated by the establishment of an ELISA with W261 as the capturing antibody (Fig. 3).

A recently published study demonstrated the detection of infectious and noninfectious aggregates of the prion protein by PrPSc-specific monoclonal antibodies, suggesting that these MAbs recognize structural elements common to infectious and noninfectious aggregates of the prion protein (6). Since in our study the interactions of the PrPSc-specific antibodies generated with noninfectious prion protein aggregates were not analyzed, we cannot exclude the possibility that these antibodies might also bind to noninfectious aggregates of the prion protein in addition to binding to PK-resistant, supposedly infectious prions (Fig. 1B).

The intuitive concept of shielding the causative agent of a disease by highly specific immune binding, e.g., neutralization of a virus by antibodies, has long been held up for prion diseases. However, early studies argued that antibodies binding to PrPC in addition to PrPSc had improved prion clearance in permanently scrapie infected cells (5a). Here we demonstrate the complete lack of PrP conversion inhibition by PrPSc-specific MAb W261 in vivo, even if treatment of cells was continued for more than 3 months, whereas under the same conditions, the universal MAb W226, lacking conformation specificity, was effective (Fig. 5; see also below). The reasons for the absence of antiprion activity for MAb W261 may include the localization of PrPSc in cellular compartments that are not accessible to PrPSc-specific antibodies. If so, there would be no interference with the templating function of PrPSc in the process of prion replication and/or prion storage, and thus, PrPSc with a long half-life would be present. It is not certain whether a generalization that all PrPSc-specific MAbs lack antiprion activity can therefore be inferred, but the fact that no such effect has been published so far could point to this possibility.

Interestingly, the only published PrPSc-specific peptide ligand showing antiprion activity in cell culture is a retroinverso \(n\)-peptide of the complementarity-determining region (CDR) of the MAb W226 heavy chain that, in contrast to full-length W226, proved PrPSc specific, although the \(n\)-peptide has to be used at relatively high concentrations (27).

In contrast to W261, the universal MAb W226, recognizing both PrPC and PrPSc, cleared prions from ScN2a cells, as
TABLE 2. Isotypes and epitopes of the monoclonal antibodies generated in this study

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Isotype</th>
<th>Epitope</th>
</tr>
</thead>
<tbody>
<tr>
<td>W123</td>
<td>IgG2b</td>
<td>145- WEDRYYREN-153</td>
</tr>
<tr>
<td>W187</td>
<td>IgG2b</td>
<td>WGQPHGG (octarepeat motif)</td>
</tr>
<tr>
<td>W226</td>
<td>IgG1</td>
<td>145- WEDRYYREN-153</td>
</tr>
<tr>
<td>W261</td>
<td>IgG1</td>
<td>Unknown*</td>
</tr>
<tr>
<td>W756</td>
<td>IgG2a</td>
<td>145- WEDRYYREN-153</td>
</tr>
<tr>
<td>W827</td>
<td>IgG1</td>
<td>145- WEDRYYREN-153</td>
</tr>
</tbody>
</table>

* Amino acids are numbered according to the hamster prion protein sequence.

The epitope of W261 is thought to be a conformational epitope located in the PK-resistant core of PrP\textsuperscript{Sc}.

validated by a bioassay (Fig. 5D). This effect has also been shown by many other universal anti-PrP MABs targeting helix 1 of PrP (12, 33). MAb W226 was therefore chosen for a therapeutic trial against prion infection. So far, the successful trial of White et al. with antibodies ICSM18 and ICSM35 leading to complete protection from peripheral prion infection stands alone as the only published report of successful administration of antibodies against prion disease. Here we precisely copied the treatment protocol of White et al. except that the mouse strain inoculated was C57BL/6 rather than FVB and the strain of experimental protocols, we draw the important conclusion that the therapeutic success of antibodies against peripheral prion infection must be influenced either by the strain of mouse inoculated, the specific pharmacodynamic or pharmacokinetic characteristics of the antibody itself, or perhaps both.

Starting antibody administration either 28 days or 2 days after i.p. inoculation did not lead to protection against prion disease to the degree published by White et al., although a single mouse in each of two long-term treatment groups survived for more than 600 days (Fig. 6A). Of note, the avidity of bivalent W226 compared to that of monovalent scW226 did not seem to play a major role with regard to the antiprion effects. From these experiments, and considering the similarity of experimental protocols, we draw the important conclusion that the therapeutic success of antibodies against peripheral prion infection must be influenced either by the strain of mouse inoculated, the specific pharmacodynamic or pharmacokinetic characteristics of the antibody itself, or perhaps both.

A sequence comparison between the antibodies reveals significant differences between W226 and ICSM18, especially in the hypervariable CDR regions (Fig. 7). These sequence differences could account for differences in the half-life and distribution of the antibody in vivo; different affinities or other binding characteristics could equally make a decisive difference. In summary, the ability of an antibody to cure ScN2a cells, even if confirmed by a bioassay, does not predict successful application in a therapeutic trial. A similar finding was recently reported for quinacrine, a small molecule with clear antiprion activity in ScN2a cells (18), which also failed in a therapeutic trial (14). This failure, despite the fact that pharmacokinetic obstacles such as the multigrain resistance complex were circumvented successfully, was attributed to an evolution of quinacrine-resistant prions (14). It remains to be seen whether such an explanation could also account for the inefficiency of W226 versus ICSM18 or if different factors account for the divergent results between these antibodies.

ACKNOWLEDGMENTS

This work was supported by the TSE program Baden-Württemberg (grant 729.59-7/1, to L.S.), by EU-Europion FFP (to L.S.), by EU-FP6 Antepron (LSHB-CT-2006-019090) and EU-FP7 Priority (grant 222857) to L.S. and C.K., and by EU-FP6 StrainBarrier (Food 3B 023183, to C.K.). The brain bank in the National CID Surveillance Unit, Edinburgh, United Kingdom, is supported by the Medical Research Council.

We thank Ulrich Wulle, Silke Gaedt, and Jacqueline Schmid for excellent technical assistance, Simone Nebrich for the histological staining of brain sections, Adriano Aguzzi and Magda Polymenidou (Zurich, Switzerland) for providing the POM-1 antibody and the tga20 and Prnp\textsuperscript{2020} mice, Edward Hooper (Fort Collins, CO) for kindly providing CWD brain material, Michael Beckes for providing the 263K strain, Eberhard Burkhardt (Giessen, Germany) for kindly providing control animal brain tissue, and Bjorn Schröder for critical reading of the manuscript.

REFERENCES

41. Reference deleted.